Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.35 |
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.34 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18281370 | 0.99 | CA9 (0.41) | CA9ALBCA1CA2CA12 | |
| SCHEMBL18281369 | 0.99 | CA9 (0.41) | CA9ALBCA1CA2CA12 | |
| SCHEMBL19605919 | 0.95 | CA9 (0.39) | CA9ALBCA1CA2CA12 | |
| SCHEMBL19605828 | 0.92 | CA9 (0.38) | CA9ALBCA1CA2CA12 | |
| SCHEMBL18292015 | 0.91 | DGAT1 (0.37) | DGAT1FOLH1CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL20515160 | 0.91 | CA9 (0.43) | CA9ALBCA1CA2CA12 | |
| SCHEMBL20515159 | 0.91 | CA9 (0.43) | CA9ALBCA1CA2CA12 | |
| SCHEMBL29410425 | 0.91 | CA9 (0.43) | CA9ALBCA1CA2CA12 | |
| SCHEMBL29410424 | 0.91 | CA9 (0.43) | CA9ALBCA1CA2CA12 | |
| SCHEMBL18291960 | 0.90 | CA9 (0.42) | CA9ALBCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192699-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192699-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | CA9, CA14, CA13 | CA9 1/4885ALB 3084/4885CA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.